Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients
Sponsor: Changzhou No.2 People's Hospital
A observational or N/A phase clinical study on Biomarkers and FH-Deficient RCC, this trial is ongoing. The trial is conducted by Changzhou No.2 People's Hospital and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Oct 2025 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Sep 2023 — Jul 2024 [monthly]
Recruiting
-
Sep 2022 — Sep 2023 [monthly]
Recruiting
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changzhou No.2 People's Hospital
- First Affiliated Hospital of Fujian Medical University
- First Affiliated Hospital, Sun Yat-Sen University
- Fudan University
- Jiangxi Provincial People's Hopital
- Peking University First Hospital
- RenJi Hospital
- Ruijin Hospital
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Shanghai 10th People's Hospital
- Shanghai Zhongshan Hospital
- Tongji Hospital
- Zhejiang Provincial People's Hospital
- Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .